| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-K50799972 | CTRPv2 | pan-cancer | AAC | -0.0097 | 0.8 |
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0096 | 0.8 |
| mRNA | NVP-BEZ235 | CTRPv2 | pan-cancer | AAC | 0.01 | 0.8 |
| mRNA | dexamethasone | CTRPv2 | pan-cancer | AAC | 0.008 | 0.8 |
| mRNA | RAF265 | CTRPv2 | pan-cancer | AAC | -0.0097 | 0.8 |
| mRNA | FSC231 | CTRPv2 | pan-cancer | AAC | 0.017 | 0.8 |
| mRNA | bendamustine | CTRPv2 | pan-cancer | AAC | 0.0086 | 0.8 |
| mRNA | BRD-K63431240 | CTRPv2 | pan-cancer | AAC | -0.008 | 0.8 |
| mRNA | LE-135 | CTRPv2 | pan-cancer | AAC | -0.0079 | 0.8 |
| mRNA | neratinib | CTRPv2 | pan-cancer | AAC | -0.0076 | 0.8 |